Effect of nitric oxide and hydrogen sulfide donors on blood clotting parameters: 612.062:612.1+616.005

Abstract

Summary. Background. Nitric oxide (NO) and hydrogen sulfide (H2S) are known as an endogenously produced gaseous signaling molecules which has been recognized recently as gasotransmitters and regulate a number of vital functions, while the effect of these small gaseous molecules (especially H2S) on the complex blood coagulation process needs to be clarified. Objectives: to evaluate the effect of NO and H2S on the whole blood coagulation process, platelet aggregation and plasma fibrinolytic activity. Patients/Methods. Venous blood of healthy volunteers (n = 27) was used for the estimation of blood coagulation properties. Whole blood clotting, platelet aggregation, and plasma fibrinolytic activity were assessed in the presence of donors of nitric oxide — sodium nitroprusside (SNP) and Spermine NONOate and donors of hydrogen sulfide — sodium hydrosulfide (NaHS) and GYY4137 just like in their absence (control). Results. In the presence of NO donors, a pronounced decrease in platelet aggregation, inhibition of the intensity of contact coagulation and the polymerization stage of blood coagulation, and the intensity of total coagulation were revealed that indicates a slowdown of all fibrinogenesis stages from initiation to the cross-linked fibrin formation. Plasma fibrinolytic activity increased in the presence of NO donors, and remained practically unchanged in the presence of H2S donors. H2S donors increased platelet aggregation activity, followed by the intensification of the contact coagulation phase of whole blood. The influence of H2S on the subsequent stages of the blood coagulation process generally coincided with NO effect — a decrease in clot polymerization intensity and other stages of fibrinogenesis was registered. Conclusions. The effect of both gasotransmitters is realized both at the initial stages of blood coagulation, causing changes in platelet aggregation, and at the stages of fibrinogenesis; H2S influence on clot retraction and lysis was not revealed.

References:

1. Giuffrè A., Vicente J.B. Hydrogen sulfide biochemistry and inter‐ play with other gaseous mediators in mammalian physiology. Oxid Med Cell Longev. 2018;2018:6290931. DOI: 10.1155/2018/6290931. 

2. Gresele P., Momi S., Guglielmini G. Nitric oxide‐enhancing or ‐releasing agents as antithrombotic drugs. Biochem Pharmacol. 2019;166:300–12. DOI: 10.1016/j.bcp.2019.05.030. 

3. Newby D.E., Wright R.A., Dawson I. et al. The L‐arginine/nitric oxide pathway contributes to the acute release of tissue plasmin‐ ogen activator in vivo in man. Cardiovasc Res. 1998;38(2):485–92. DOI: 10.1016/s0008–6363(98)00017–0.
4. Simon D.I., Stamler J.S., Loh E. et al. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol. l995;26(2):339–42. DOI: 10.1097/00005344–199508000–00022. 

5. Tanriverdi S., Koroglu O.A., Uygur O. et al. The effect of inhaled nitric oxide therapy on thromboelastogram in newborns with per‐ sistent pulmonary hypertension. Eur J Pediatr. 2014;173(10):1381– 5. DOI: 10.1007/s00431–014–2325–3. 

6. de MolA.C., van HeijstA.F.J, Brouwers M. et al. Abnormalities of coagulation related to the use of inhaled nitric oxide before extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2007;8(3):261–3. DOI: 10.1097/01.PCC.0000262888.24742.81. 

7. Zagli G., Patacchini R., Trevisani M. et al. Hydrogen sulfide inhib‐ its human platelet aggregation. Eur J Pharmacol. 2007;559(1):65– 8. DOI: 10.1016/j.ejphar.2006.12.011. 

8. Olas B., Kontek B. The possible role of hydrogen sulfide as a mod‐ ulator of hemostatic parameters of plasma. Chem Biol Interact. 2014;220:20–4. DOI: 10.1016/j.cbi.2014.06.00120–24. 

9. Truss N.J., Warner T.D. Gasotransmitters and platelets. Pharmacol Ther. 2011;132(2):196–203. DOI: 10.1016/j.pharmthera.2011.07.001. 

10. TyutrinI.I., UdutV.V.Low‐frequency piezothromboelastogra‐ phy of whole blood: algorhytms for diagnostics and corrections of hemostasiological disorders. Tomsk, 2016. 170 pp. (In Russ.). 

11. Gabbasov Z.A., Popov E.G., Gavrilov I. Yu. et al. New high sensi‐ tive method of analysis of platelet aggregation. Laboratornoe delo. 1989;(10):15–8. (In Russ.).

1. Radziwon‐Balicka A., Lesyk G., Back V. et al. Differential eNOS‐sig‐ nalling by platelet subpopulations regulates adhesion and aggrega‐ Cardiovasc Res. 2017;113(14):1719–31. DOI: 10.1093/cvr/cvx179.
2. Mendelsohn M.E., O’Neill S., George D., Loscalzo J. Inhibi‐ tion of fibrinogen binding to human platelets by S‐nitroso‐N‐ J Biol Chem. 1990;265(31):19028–34.
3. Medcalf R. L. What drives “fibrinolysis”? Hämostaseologie. 2015;35(4):303–10. DOI: 10.5482/HAMO‐14–10–0050. 

4. Whyte C.S., Mitchell J.L., Mutch N.J. Platelet‐mediated modula‐ tion of fibrinolysis. Semin Thromb Hemost. 2017;43(2):115–28. DOI: 1055/s‐0036–1597283. 

5. Helms C., Kapadia S., Gilmore A. et al. Exposure of fibrinogen and thrombin to nitric oxide donor ProliNONOate affects fibrin clot properties. Blood Coagul Fibrinolysis. 2017;28(5):356–64. DOI: 1097/MBC.0000000000000602. 

6. Schini‐Kerth V.B. Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis. Transf Clin Biol. 1999;6(6):355–63. DOI: 10.1016/S1246–7820(00)88980–6. 

7. Radomski M.W., Palmer R.M.J., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2(8765):1057–8. DOI: 10.1016/s0140–6736(87)91481–4. 

8. Morel A., Malinowska J., Olas B. Hydrogen sulfide changes adhe‐ sive properties of fibrinogen and collagen in vitro. Platelets. 2014;25(2):147–9. DOI: 10.3109/09537104.2012.737490. 

9. Olas B., Brodek P., Kontek B. The effect of hydrogen sulfide on dif‐ ferent parameters of human plasma in the presence or absence of exogenous reactive oxygen species. Antioxidants (Basel). 2019;8(12):610–9. DOI: 10.3390/antiox8120610. 

10. Yagdi E., Cerella C., Dicato M., Diederich M. Garlic‐derived natu‐ ral polysulfanes as hydrogen sulfide donors: Friend or foe? Food Chem Toxicol. 2016;95:219–33. DOI: 10.1016/j.fct.2016.07.016. 

11. Szabo C., Papapetropoulos A. International union of basic and clin‐ ical pharmacology. CII: pharmacological modulation of H2S lev‐ els: H2S donors and H2S biosynthesis inhibitors. Pharmacol Rev. 2017;69(4):497–564. DOI: 10.1124/pr.117.014050.